Review





Similar Products

vhl based protac 3i  (Arvinas Inc)
86
Arvinas Inc vhl based protac 3i
Vhl Based Protac 3i, supplied by Arvinas Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vhl-based+protacs/degrader+er+vepdegestrant/bio_rxiv__64898__2026__01__30__702304-158-8-6
Average 86 stars, based on 1 article reviews
vhl based protac 3i - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
vhl based protac asp3082  (Astellas)
86
Astellas vhl based protac asp3082
Vhl Based Protac Asp3082, supplied by Astellas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vhl-based+protacs/asp3082/pm41166656-29-24-30
Average 86 stars, based on 1 article reviews
vhl based protac asp3082 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
vhl-based protacs from the bromodomain ligands  (Boehringer Ingelheim)
90
Boehringer Ingelheim vhl-based protacs from the bromodomain ligands
Vhl Based Protacs From The Bromodomain Ligands, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vhl-based+protacs/vhl+based+protacs+from+the+bromodomain+ligands/10__1146_slash_annurev___cancerbio___061824___105806-162-4-15
Average 90 stars, based on 1 article reviews
vhl-based protacs from the bromodomain ligands - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
vhl-based protacs  (Arvinas Inc)
90
Arvinas Inc vhl-based protacs
The first disclosed VHL ligand-containing <t>PROTACs.</t> (a) BRD4 targeting PROTAC MZ-1 . (b) ER PROTAC 4 .
Vhl Based Protacs, supplied by Arvinas Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vhl-based+protacs/vhl+based+protacs/pmc11875441-405-9-4
Average 90 stars, based on 1 article reviews
vhl-based protacs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
vhl based protacs  (MedChemExpress)
94
MedChemExpress vhl based protacs
The first disclosed VHL ligand-containing <t>PROTACs.</t> (a) BRD4 targeting PROTAC MZ-1 . (b) ER PROTAC 4 .
Vhl Based Protacs, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vhl-based+protacs/GNE-987/pm38809610__bc4c00124_si_001-38-21-24
Average 94 stars, based on 1 article reviews
vhl based protacs - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
vhl-based protac molecule  (Arvinas Inc)
90
Arvinas Inc vhl-based protac molecule
The first disclosed VHL ligand-containing <t>PROTACs.</t> (a) BRD4 targeting PROTAC MZ-1 . (b) ER PROTAC 4 .
Vhl Based Protac Molecule, supplied by Arvinas Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vhl-based+protacs/vhl+based+protac+molecule/pm36678785-60-7-10
Average 90 stars, based on 1 article reviews
vhl-based protac molecule - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
vhl-based protacs  (Amgen)
90
Amgen vhl-based protacs
The first disclosed VHL ligand-containing <t>PROTACs.</t> (a) BRD4 targeting PROTAC MZ-1 . (b) ER PROTAC 4 .
Vhl Based Protacs, supplied by Amgen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vhl-based+protacs/vhl+based+protacs/pm35295813-2-11-35
Average 90 stars, based on 1 article reviews
vhl-based protacs - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


The first disclosed VHL ligand-containing PROTACs. (a) BRD4 targeting PROTAC MZ-1 . (b) ER PROTAC 4 .

Journal: Expert Opinion on Therapeutic Patents

Article Title: A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)

doi: 10.1080/13543776.2024.2446232

Figure Lengend Snippet: The first disclosed VHL ligand-containing PROTACs. (a) BRD4 targeting PROTAC MZ-1 . (b) ER PROTAC 4 .

Article Snippet: Work in 2019 by Arvinas disclosed a range of VHL-based PROTACs that degrade SMARCA2/4 proteins which included a range of different heterocycles ( ) [ ].

Techniques:

Early PROTACs exemplifying the various exit vectors on the VHL ligand. (a) The five primary exit vector positions within the VH032 ligand. (b) Cocrystal structure of VH032 bound to VCB (PDB 4W9H). (c, d) BRD2/3/4 targeting PROTACs ARV-771 , AT1 and AT7 . (e) BRD7/9 targeting PROTAC VZ185 . (f) AR targeting PROTAC ARD-69 .

Journal: Expert Opinion on Therapeutic Patents

Article Title: A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)

doi: 10.1080/13543776.2024.2446232

Figure Lengend Snippet: Early PROTACs exemplifying the various exit vectors on the VHL ligand. (a) The five primary exit vector positions within the VH032 ligand. (b) Cocrystal structure of VH032 bound to VCB (PDB 4W9H). (c, d) BRD2/3/4 targeting PROTACs ARV-771 , AT1 and AT7 . (e) BRD7/9 targeting PROTAC VZ185 . (f) AR targeting PROTAC ARD-69 .

Article Snippet: Work in 2019 by Arvinas disclosed a range of VHL-based PROTACs that degrade SMARCA2/4 proteins which included a range of different heterocycles ( ) [ ].

Techniques: Plasmid Preparation

VHL-based PROTACs patented by the University of Michigan in 2024. SMARCA2 degradation reported from HiBiT assay.

Journal: Expert Opinion on Therapeutic Patents

Article Title: A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)

doi: 10.1080/13543776.2024.2446232

Figure Lengend Snippet: VHL-based PROTACs patented by the University of Michigan in 2024. SMARCA2 degradation reported from HiBiT assay.

Article Snippet: Work in 2019 by Arvinas disclosed a range of VHL-based PROTACs that degrade SMARCA2/4 proteins which included a range of different heterocycles ( ) [ ].

Techniques:

Indazole modifications introduced in PROTACs by Kymera in 2023. Degradation at 6 h in MOLT-4 in ELISA assay.

Journal: Expert Opinion on Therapeutic Patents

Article Title: A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)

doi: 10.1080/13543776.2024.2446232

Figure Lengend Snippet: Indazole modifications introduced in PROTACs by Kymera in 2023. Degradation at 6 h in MOLT-4 in ELISA assay.

Article Snippet: Work in 2019 by Arvinas disclosed a range of VHL-based PROTACs that degrade SMARCA2/4 proteins which included a range of different heterocycles ( ) [ ].

Techniques: Enzyme-linked Immunosorbent Assay

SMARCA degrading PROTACs patented by Arvinas bearing modification to the RHS thiazole.

Journal: Expert Opinion on Therapeutic Patents

Article Title: A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)

doi: 10.1080/13543776.2024.2446232

Figure Lengend Snippet: SMARCA degrading PROTACs patented by Arvinas bearing modification to the RHS thiazole.

Article Snippet: Work in 2019 by Arvinas disclosed a range of VHL-based PROTACs that degrade SMARCA2/4 proteins which included a range of different heterocycles ( ) [ ].

Techniques: Modification

BRAF PROTACs patented by Arvinas containing several changes to the methyl thiazole region.

Journal: Expert Opinion on Therapeutic Patents

Article Title: A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)

doi: 10.1080/13543776.2024.2446232

Figure Lengend Snippet: BRAF PROTACs patented by Arvinas containing several changes to the methyl thiazole region.

Article Snippet: Work in 2019 by Arvinas disclosed a range of VHL-based PROTACs that degrade SMARCA2/4 proteins which included a range of different heterocycles ( ) [ ].

Techniques:

Halo-phenyl containing KRAS PROTACs patented by Erasca.

Journal: Expert Opinion on Therapeutic Patents

Article Title: A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)

doi: 10.1080/13543776.2024.2446232

Figure Lengend Snippet: Halo-phenyl containing KRAS PROTACs patented by Erasca.

Article Snippet: Work in 2019 by Arvinas disclosed a range of VHL-based PROTACs that degrade SMARCA2/4 proteins which included a range of different heterocycles ( ) [ ].

Techniques:

Small group replacements of Me-thiazole. (a) SMARCA2 PROTACs from Foghorn therapeutics containing smaller groups in place of the thiazole. (b) BCL-xL degrader 362 by Kymera containing an alkyne moiety.

Journal: Expert Opinion on Therapeutic Patents

Article Title: A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)

doi: 10.1080/13543776.2024.2446232

Figure Lengend Snippet: Small group replacements of Me-thiazole. (a) SMARCA2 PROTACs from Foghorn therapeutics containing smaller groups in place of the thiazole. (b) BCL-xL degrader 362 by Kymera containing an alkyne moiety.

Article Snippet: Work in 2019 by Arvinas disclosed a range of VHL-based PROTACs that degrade SMARCA2/4 proteins which included a range of different heterocycles ( ) [ ].

Techniques:

Ester pro-drug masking of hydroxyproline. (a) PROTACs with modified Hyp groups that degrade SMARCA2/4 reported by Aurigene in 2019. D (100 nM) = degradation of SMARCA2 achieved after compound treatment at 100 nM. ‘-’ indicates data not reported. (b) PTK6 targeting PROTAC 373 .

Journal: Expert Opinion on Therapeutic Patents

Article Title: A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)

doi: 10.1080/13543776.2024.2446232

Figure Lengend Snippet: Ester pro-drug masking of hydroxyproline. (a) PROTACs with modified Hyp groups that degrade SMARCA2/4 reported by Aurigene in 2019. D (100 nM) = degradation of SMARCA2 achieved after compound treatment at 100 nM. ‘-’ indicates data not reported. (b) PTK6 targeting PROTAC 373 .

Article Snippet: Work in 2019 by Arvinas disclosed a range of VHL-based PROTACs that degrade SMARCA2/4 proteins which included a range of different heterocycles ( ) [ ].

Techniques: Modification

Folate caged PROTACs from BIDMC targeting BRD, MEK and AKT proteins respectively.

Journal: Expert Opinion on Therapeutic Patents

Article Title: A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)

doi: 10.1080/13543776.2024.2446232

Figure Lengend Snippet: Folate caged PROTACs from BIDMC targeting BRD, MEK and AKT proteins respectively.

Article Snippet: Work in 2019 by Arvinas disclosed a range of VHL-based PROTACs that degrade SMARCA2/4 proteins which included a range of different heterocycles ( ) [ ].

Techniques: